Key result
Apparent treatment resistant hypertension was associated with an increased risk of >30% eGFR loss in patients with type 2 diabetes and stage 3 CKD (OR 1.31; P<0.007).
Why the study?
Does apparent treatment resistant hypertension and tight blood pressure control affect the progression of chronic kidney disease in patients with type 2 diabetes and hypertension?
Cohort (n=2,778)
Does apparent treatment resistant hypertension and tight blood pressure control affect the progression of chronic kidney disease in patients with type 2 diabetes and hypertension?
Odds Ratio: 1.31
p-value: p=<0.007
In patients with type 2 diabetes and stage 3 CKD, apparent treatment resistant hypertension is associated with faster eGFR loss, and tight blood pressure control paradoxically increases the risk of eGFR reduction in this subgroup.
Authors
No takes yet. Share an insight, caveat, or question.
May warrant closer eGFR monitoring in type 2 diabetes with stage 3 CKD; leaves open optimal BP targets.
Viazzi et al. (2018) conducted a cohort in Type 2 diabetes, hypertension, and stage 3 chronic kidney disease (n=2,778). Apparent treatment resistant hypertension (aTRH) vs. Non-aTRH was evaluated on eGFR loss >30% from baseline (OR 1.31, p=<0.007). Apparent treatment resistant hypertension was associated with an increased risk of >30% eGFR loss in patients with type 2 diabetes and stage 3 CKD (OR 1.31; P<0.007).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: